VGX-100
/ Opthea
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
September 29, 2021
"GX88, VGX3100, DNA vaccines for cervical cancer"
(@aLwOmbaT)
Clinical • Cervical Cancer • Oncology • Solid Tumor
November 02, 2020
"#Inovio $INO #INO4800 #INO5401 #GBM data on the 19th #VIN #AIN data #ZIKA data #SNO2020 #VGX3100 $REGN"
(@DelawareHere)
Infectious Disease
November 04, 2020
"#Inovio $INO #INO4800 #INO5401 #GBM data on the 19th #VIN #AIN data #ZIKA data #SNO2020 #VGX3100"
(@JPPerry11)
Infectious Disease
January 09, 2012
Circadian commences first phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients
(Circadian)
- Circadian Technologies has commenced the first P1 trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre; Study will examine the safety & tolerability of escalating doses of VGX-100 in pts with adv solid tumours who have no other standard treatment options both as a monotherapy & also when used in combination with other anti-angiogenic agents; Results are expected in H2 2012
Anticipated P1 data • P1 trial initiation • Oncology
February 28, 2019
"INO has a drug in phase 3 VGX3100 for cervical dysplasia, a precancer. Do you have any opinions on this drug?"
(@richard_diggler)
P3 data
January 07, 2019
"My favorite beaten up biotech stock to make huge gains in 19 is $INO. @InovioPharma Fantastic partnerships with @MedImmune @genentech @Regeneron @parkerici @CEPIvaccines @niaid @TheWistar @DARPA #HIV #catalysts very close w/100% safety profile in all trials. closely #vgx3100"
(@pquirke100)
Clinical • Licensing / partnership
1 to 6
Of
6
Go to page
1